Expression of CXCR4 in Patients With Systemic Lupus Erythematosus
NCT04799730 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2021-03-16
Summary
The objective of this study is to estimate the possible role of CD184 in the pathogenesis of SLE; comparing its level among SLE cases to healthy controls.
Conditions
Sponsors & Collaborators
-
Sohag University
lead OTHER
Eligibility
- Min Age
- 16 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-05-31
- Primary Completion
- 2021-11-30
- Completion
- 2022-05-31
More Related Trials
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of CM355 in Patients With Systemic Lupus Erythematosus
NCT07104344 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital
NCT04756492 ·Status: UNKNOWN
-
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
NCT04440566 ·Status: COMPLETED ·Phase: NA
-
The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Ratio in Systemic Lupus Erythematosus Patients
NCT06404723 ·Status: NOT_YET_RECRUITING
-
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
NCT00042523 ·Status: COMPLETED
-
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
NCT05866861 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients
NCT06313151 ·Status: RECRUITING
-
Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease
NCT02270710 ·Status: WITHDRAWN
-
A Model About the Response of Belimumab in SLE
NCT04893161 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
NCT07339332 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Haematological Indices in Systemic Lupus Erythematosus
NCT04110184 ·Status: UNKNOWN
-
A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus
NCT00541749 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.
NCT06294483 ·Status: ENROLLING_BY_INVITATION
-
Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
NCT05724940 ·Status: UNKNOWN
-
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
NCT06791772 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
NCT07102030 ·Status: RECRUITING
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
NCT07144514 ·Status: NOT_YET_RECRUITING
-
Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus
NCT06796569 ·Status: RECRUITING
-
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
NCT07177911 ·Status: RECRUITING ·Phase: PHASE1
-
New Signaling Pathway Targeting Systemic Lupus Erythematosus
NCT03984227 ·Status: UNKNOWN
-
Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
NCT00004643 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
NCT07031713 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT06886919 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1